Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers After Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-13-0286
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Profiling Molecular Regulators of Recurrence in Chemorefractory Triple-Negative Breast Cancers

Breast Cancer Research
Cancer ResearchOncology
2019English

Molecular Stratification of Triple-Negative Breast Cancers

Oncologist
Cancer ResearchMedicineOncology
2010English

Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Impact of Molecular Subtype Conversion of Breast Cancers After Neoadjuvant Chemotherapy on Clinical Outcome

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Identification of Novel Therapeutic Targets for Triple-Negative Breast Cancer

2012English

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity Before and After Neoadjuvant Chemotherapy

Cancers
Cancer ResearchOncology
2019English

Expanded Molecular Profiling of Myxofibrosarcoma Reveals Potentially Actionable Targets

Modern Pathology
Forensic MedicinePathology
2017English

Genetic Variations in Triple-Negative Breast Cancers Undergoing Neo-Adjuvant Chemotherapy

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy